Analyst Price Targets — CLDX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 23, 2026 1:31 pm | Thomas Smith | Leerink Partners | $88.00 | $31.19 | TheFly | Celldex price target raised to $88 from $70 at Leerink |
| September 23, 2026 10:27 am | — | Morgan Stanley | $57.00 | $33.51 | TheFly | Celldex price target raised to $57 from $50 at Morgan Stanley |
| September 22, 2026 3:28 pm | Joseph Pantginis | H.C. Wainwright | $64.00 | $33.75 | TheFly | Celldex price target raised to $64 from $42 at H.C. Wainwright |
| September 22, 2026 2:21 pm | Alex Thompson | Stifel Nicolaus | $68.00 | $33.57 | StreetInsider | Stifel Reiterates Buy Rating on Celldex Therapeutics (CLDX) |
| September 10, 2026 11:28 am | Judah Frommer | Morgan Stanley | $50.00 | $38.78 | TheFly | Celldex price target raised to $50 from $46 at Morgan Stanley |
| August 7, 2026 9:29 am | — | Barclays | $53.00 | $41.56 | TheFly | Celldex price target raised to $53 from $48 at Barclays |
| July 29, 2026 10:08 am | — | Wells Fargo | $72.00 | $35.58 | TheFly | Celldex price target raised to $72 from $48 at Wells Fargo |
| July 22, 2026 11:34 am | — | Cantor Fitzgerald | $61.00 | $35.66 | TheFly | Celldex price target lowered to $61 from $67 at Cantor Fitzgerald |
| July 22, 2026 11:05 am | — | Wells Fargo | $48.00 | $35.66 | TheFly | Celldex price target lowered to $48 from $54 at Wells Fargo |
| July 22, 2026 10:49 am | — | Morgan Stanley | $40.00 | $35.66 | TheFly | Celldex price target lowered to $40 from $44 at Morgan Stanley |
Latest News for CLDX
NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Celldex Therapeutics, Inc. (NASDAQ: CLDX) on behalf of the company's shareholders. The investigation seeks to determine whether Celldex Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.
Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Senti Biosciences (NASDAQ: SNTI - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations. Insider and Institutional Ownership 25.7% of Senti Biosciences
Celldex Therapeutics, Inc. (NASDAQ: CLDX - Get Free Report) gapped down before the market opened on Tuesday. The stock had previously closed at $37.89, but opened at $36.60. Celldex Therapeutics shares last traded at $35.18, with a volume of 3,679,133 shares traded. Celldex Therapeutics News Roundup Here are the key news stories impacting Celldex Therapeutics
Celldex Therapeutics (NASDAQ: CLDX) reported positive top-line results from its two Phase III EMBARQ-CSU studies of barzolvolimab in adults with chronic spontaneous urticaria, or CSU, who remained symptomatic despite H1 antihistamine treatment. The company said both evaluated dose regimens met the primary endpoint and all key secondary endpoints, with efficacy sustained or deepening through 24 weeks.
Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CLDX.
U.S. House Trading
No House trades found for CLDX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.